Supriya Lifescience Ltd, a prominent player in the pharmaceutical sector, has reported a strong financial performance for the second quarter of fiscal year 2026, demonstrating resilience and growth in a competitive market.

Revenue and Profitability

The company's revenue from operations witnessed a significant quarter-on-quarter increase, rising to ₹2,794.40 million in Q2 FY2026 from ₹2,463.50 million in the previous quarter. This robust top-line growth underscores Supriya Lifescience's expanding market presence and effective sales strategies.

The company's profitability also showed improvement, with net profit increasing to ₹504.27 million, compared to ₹461.49 million in the prior quarter. This growth in bottom-line figures reflects the company's ability to manage costs effectively while driving revenue growth.

Half-Year Performance

For the half year ended September 30, 2025, Supriya Lifescience reported total revenue from operations of ₹5,257.90 million, with a net profit of ₹965.76 million. These figures demonstrate the company's consistent performance over a longer period.

Financial Position

As of September 30, 2025, Supriya Lifescience maintains a strong balance sheet with cash and cash equivalents standing at ₹992.68 million. This healthy liquidity position indicates the company's financial stability and potential for future investments or expansion.

Corporate Governance

The financial results were approved by the Board of Directors during their meeting held on November 12, 2025. Prior to board approval, the results were reviewed by the Audit Committee and received a clean review report from the statutory auditors, underlining the company's commitment to transparency and regulatory compliance.

Conclusion

The consistent growth in revenue and profitability, coupled with a strong cash position, positions Supriya Lifescience well in the pharmaceutical sector. The company's performance in Q2 FY2026 reflects its ability to navigate market challenges and capitalize on opportunities.

Note: All figures are in Indian rupees and have been rounded to two decimal places where applicable.

Supriya Lifescience Limited, a prominent player in the pharmaceutical industry, has achieved a significant milestone with the receipt of a Good Manufacturing Practices (GMP) certificate from the World Health Organization (WHO) for its Ambernath facility. This certification marks a crucial step in the company's global expansion strategy, enabling it to conduct production and distribution operations on a worldwide scale.

WHO GMP Certification Details

The WHO conducted a GMP audit for Inhalation Dosages at Supriya Lifescience's Ambernath facility on September 2, 2025. Following the successful completion of the audit, the WHO issued the GMP certificate, declaring the facility compliant with Good Manufacturing Practices standards.

Implications of the Certification

The WHO-GMP certification brings several key advantages to Supriya Lifescience:

• Global Production Capability: The company can now carry out production at the Ambernath facility for international markets.
• Expanded Distribution Rights: Supriya Lifescience is now eligible to distribute its products in Rest of the World markets and other eligible territories.
• Quality Assurance: The certification serves as a testament to the high-quality manufacturing standards maintained at the Ambernath facility.

Company's Perspective

In a regulatory filing to the stock exchanges, Supriya Lifescience stated, "We do not expect this development to have any material impact on the current business operations or existing supplies from this facility." While the immediate financial impact may be limited, the certification positions the company for potential long-term growth in international markets.

About Supriya Lifescience Limited

Supriya Lifescience Limited is a recognized Export House with its corporate office located in Mumbai, Maharashtra. The company operates a factory in the Lote Parshuram Industrial Area, demonstrating its commitment to pharmaceutical manufacturing excellence.

This WHO GMP certification for the Ambernath facility reinforces Supriya Lifescience's position in the global pharmaceutical landscape and may open doors to new opportunities in international markets. As the company continues to expand its global footprint, stakeholders will be keen to observe how this certification translates into business growth and market penetration in the coming years.